BR112015032262A2 - composições de nanopartículas e formulações de compostos de piperazina - Google Patents

composições de nanopartículas e formulações de compostos de piperazina

Info

Publication number
BR112015032262A2
BR112015032262A2 BR112015032262A BR112015032262A BR112015032262A2 BR 112015032262 A2 BR112015032262 A2 BR 112015032262A2 BR 112015032262 A BR112015032262 A BR 112015032262A BR 112015032262 A BR112015032262 A BR 112015032262A BR 112015032262 A2 BR112015032262 A2 BR 112015032262A2
Authority
BR
Brazil
Prior art keywords
nanoparticle compositions
piperazine compound
compound formulations
relates
present
Prior art date
Application number
BR112015032262A
Other languages
English (en)
Inventor
Ahn Chang-Ho
Joong Kim Deog
Bok Lee Young
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of BR112015032262A2 publication Critical patent/BR112015032262A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)

Abstract

a presente invenção refere-se a composições de nanopartículas de compostos de piperazina estáveis durante o armazenamento. a presente invenção também refere-se às composições farmacêuticas compreendendo as composições de nanopartículas que são úteis para o tratamento e para a prevenção de doenças proliferativas incluindo o câncer.
BR112015032262A 2013-06-28 2014-06-27 composições de nanopartículas e formulações de compostos de piperazina BR112015032262A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840800P 2013-06-28 2013-06-28
PCT/US2014/044714 WO2014210543A1 (en) 2013-06-28 2014-06-27 Nanoparticulate compositions and formulations of piperazine compounds

Publications (1)

Publication Number Publication Date
BR112015032262A2 true BR112015032262A2 (pt) 2017-07-25

Family

ID=52115818

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015032262A BR112015032262A2 (pt) 2013-06-28 2014-06-27 composições de nanopartículas e formulações de compostos de piperazina

Country Status (10)

Country Link
US (2) US9744167B2 (pt)
EP (1) EP3013321B1 (pt)
JP (1) JP6063090B2 (pt)
KR (1) KR101741344B1 (pt)
CN (1) CN105530919A (pt)
AU (1) AU2014302085B2 (pt)
BR (1) BR112015032262A2 (pt)
CA (1) CA2913611C (pt)
MX (1) MX363378B (pt)
WO (1) WO2014210543A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10386568B2 (en) * 2015-06-24 2019-08-20 Intel Corporation Combined rear cover and enhanced diffused reflector for display stack
EP3344250A2 (en) 2015-09-04 2018-07-11 Rexahn Pharmaceuticals, Inc. Quinoxalinyl-piperazinamide methods of use
EP3630120A4 (en) 2017-05-30 2021-01-13 Rhoshan Pharmaceuticals, Inc. STABLE, STERILE AND CRYSTALLINE O-ACETYLSALICYLIC ACID (ASPIRIN) BOTTLE DEPOSIT
EP3928772A1 (en) 2020-06-26 2021-12-29 Algiax Pharmaceuticals GmbH Nanoparticulate composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
KR100396738B1 (ko) 1999-03-03 2003-09-03 삼진제약주식회사 피페라진 유도체 및 그 제조방법
PL1819698T3 (pl) 2004-11-17 2011-08-31 Rexahn Pharmaceuticals Inc Pochodne 1-[(6-podstawione alkoksychinoksalinylo)aminokarbonylo]-4-(hetero)arylopiperazyny
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
WO2011146583A2 (en) * 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
CN103044437B (zh) * 2012-12-21 2015-08-26 上海交通大学 用于治疗肿瘤的两亲性缀合物纳米颗粒及制备方法、应用

Also Published As

Publication number Publication date
AU2014302085B2 (en) 2019-04-11
MX363378B (es) 2019-03-21
MX2015017539A (es) 2016-04-26
US20180008601A1 (en) 2018-01-11
CA2913611C (en) 2019-12-24
EP3013321A1 (en) 2016-05-04
US10052321B2 (en) 2018-08-21
US9744167B2 (en) 2017-08-29
KR101741344B1 (ko) 2017-05-29
US20150004234A1 (en) 2015-01-01
EP3013321B1 (en) 2020-12-09
AU2014302085A1 (en) 2015-12-17
JP6063090B2 (ja) 2017-01-18
WO2014210543A1 (en) 2014-12-31
CA2913611A1 (en) 2014-12-31
JP2016515588A (ja) 2016-05-30
CN105530919A (zh) 2016-04-27
KR20150123218A (ko) 2015-11-03
EP3013321A4 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
CY1122718T1 (el) Σκευασμα συνδυασμου δυο αντι-ιικων ενωσεων
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
DOP2015000274A (es) Compuestos químicos
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201500926A1 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
BR112016012862A2 (pt) formulações para vacinas para neoplasia
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
CR20150571A (es) Compuestos y composiciones terapéuticos
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
NI201500096A (es) Compuesto químicos
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
CO7101239A2 (es) Composiciones derivadas de la quitosana
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
BR112015032262A2 (pt) composições de nanopartículas e formulações de compostos de piperazina
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
CR20160175A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CU20150048A7 (es) Compuestos heteroaromáticos como ligandos d1 de dopamina
BR112016028017A2 (pt) Inibidor de quinase alk e método de preparação e usos do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2676 DE 19-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.